TAAR1 Agonism: An Emerging Target in Schizophrenia Management
May 5, 2023
May 5, 2024
Mental Health, Schizophrenia
This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.
This CE activity for ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.
This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. and Otsuka America Pharmaceutical, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Pharmacists - maxium of 1.0 contact hour (0.1 CEUs) ACPE credit
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity has been designed to meet the needs of psychiatrists, nurse practitioners, physician assistants, and other advanced healthcare providers who manage patients with schizophrenia.
Although there are many treatment options for patients with schizophrenia, for more than 70 years there has been only one therapeutic approach: dopamine blockade at the post-synaptic receptor. All currently available antipsychotics work through this mechanism of action. While this is often effective for reducing the positive symptoms of schizophrenia, it typically does little to manage negative symptoms or cognitive deficits, and discontinuation rates are often high due to adverse effects such as weight gain and involuntary movement disorders.
Recent insights into other neural networks involved in the pathophysiology of schizophrenia have led to the development of novel treatments that would target different neurotransmitters, potentially improving other symptom domains while reducing the risk for metabolic and neurologic adverse effects. One of the most promising of these is agonism of the trace amine-associated receptor 1 (TAAR1), which resides intracellularly in both the pre- and post-synaptic neuron.
Join neuropsychopharmacology expert Leslie Citrome, MD, MPH, as he introduces TAAR1 agonists and other emerging therapies in the treatment of schizophrenia.
Upon completion of this activity, participants should be better able to:
- Improve clinician knowledge about current treatments for schizophrenia and gaps in management
- Describe the mechanism of action and clinical rationale for TAAR1 agonism in the treatment of schizophrenia
- Review available safety and efficacy data for emerging TAAR1 agonists under development for schizophrenia
Leslie Citrome, MD, MPH
Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
Physician Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-23-024-H01-P)
This is a knowledge-based activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integrity Continuing Education, Inc. and Global Education Group are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by Integrity Continuing Education, Inc. and Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integrity Continuing Education, Inc. and Global Education Group to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
- Leslie Citrome, MD, MPH
- Consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, Vanda
- Royalties/Publishing Income: Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-date), Wiley (Editor in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics)
- Speaker: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies
- Stocks (small number of shares of common stock): Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer purchased >10 years ago, stock options: Reviva
The Integrity Continuing Education, Inc. and Global Education Group planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of May 5, 2023 through May 5, 2024 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% and a completed activity evaluation form. Pharmacists must check the CPE Monitor to access their credits within 60 days of the activity. Credit cannot be issued after 60 days.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.
For information about ACPE accreditation of this activity, please contact Global Education Group at (303) 395-1782 or email@example.com.